The shift toward home sleep apnea testing has been accelerating for years, driven by cost considerations and patient convenience. For many straightforward cases of obstructive sleep apnea, home testing works well enough. But there’s growing evidence that this trend is resulting in missed diagnoses and inappropriate treatment decisions for a significant subset of patients.

Home sleep tests typically measure airflow, respiratory effort, and oxygen saturation. Some add body position and snoring intensity. What they don’t measure is actual sleep—there’s no EEG monitoring, no sleep staging, no ability to differentiate sleep from quiet wakefulness. The test assumes you’re sleeping during the recording period, which isn’t always true.

This creates problems for patients with insomnia, who might spend hours lying awake during the home test. Their apnea-hypopnea index gets calculated based on total recording time rather than actual sleep time, artificially lowering the severity classification. Someone with moderate sleep apnea might get classified as mild because they only slept 4 hours out of the 8-hour recording window.

Positional sleep apnea presents another diagnostic challenge. Some patients have apnea primarily or exclusively when sleeping on their back. Home tests record body position, but the data quality and reliability vary considerably between devices. If a patient inadvertently sleeps predominantly on their side during the home test night, their apnea severity will be underestimated.

Central sleep apnea is particularly problematic for home testing. While home devices theoretically distinguish central from obstructive events based on respiratory effort patterns, the reality is less clear-cut. Mixed apneas, periodic breathing, and Cheyne-Stokes respiration can be misclassified. This matters because treatment differs substantially—CPAP works well for obstructive events but can worsen some central apnea patterns.

The single-night snapshot that home testing provides misses night-to-night variability. Sleep apnea severity can fluctuate based on alcohol consumption, medication use, nasal congestion, sleep position, and sleep stage distribution. A patient might have a relatively good night during their home test and a much worse typical baseline.

Technical failures with home testing are more common than acknowledged. Sensors falling off during sleep, incorrect device setup, data recording errors—all happen frequently enough that many sleep labs automatically send patients home with devices for two nights rather than one, expecting that one will fail or produce poor quality data.

The interpretation of home sleep tests also varies considerably. Some are read by board-certified sleep physicians. Others get processed through algorithms with minimal physician oversight. The quality and thoroughness of interpretation directly impacts diagnostic accuracy, and there’s significant variation across providers.

What home testing categorically doesn’t detect is other sleep disorders. REM behavior disorder, periodic limb movement disorder, narcolepsy, and parasomnias all require in-lab polysomnography with EEG and video monitoring. Patients presenting with symptoms that could represent these conditions shouldn’t be getting home sleep tests, yet they frequently are because it’s the path of least resistance.

Insurance policies increasingly favor or mandate home testing as the first step, with in-lab studies requiring prior authorization and documented home test failure. This creates a perverse incentive structure where borderline cases that really need comprehensive evaluation get pushed through inadequate testing pathways.

The cost differential is substantial—home tests run $200-400 while in-lab polysomnography costs $2000-3000. From a healthcare system economics perspective, preferring home testing makes sense. From an individual patient diagnostic accuracy perspective, it’s more problematic.

Patient selection for home versus lab testing should be more rigorous. Ideal home test candidates are those with high pretest probability of moderate-to-severe obstructive sleep apnea, without significant comorbid conditions, and without symptoms suggesting other sleep disorders. That’s actually a fairly narrow subset of patients presenting with sleep complaints.

The American Academy of Sleep Medicine guidelines acknowledge these limitations and recommend in-lab testing for complex cases, but implementation is inconsistent. Many primary care providers aren’t familiar with the nuances and order home testing for essentially all patients with suspected sleep apnea.

Some specialists consulting with custom AI development teams are working on enhanced diagnostic algorithms that incorporate patient history, symptom patterns, and home test data to better identify cases requiring more comprehensive evaluation. It’s a reasonable approach to triaging limited sleep lab resources more effectively.

The patient experience matters too. Home testing’s convenience is real—sleeping in your own bed, maintaining your normal routine, avoiding the cost and time of an overnight lab stay. For many people, that’s worth the trade-off in diagnostic precision. The issue is ensuring patients understand what they’re gaining and losing with that choice.

Follow-up is critical but often inadequate. A negative home sleep test in someone with persistent symptoms should prompt further evaluation, not closure of the diagnostic process. Similarly, a borderline positive test might warrant confirmatory in-lab testing before committing to long-term CPAP therapy.

The technology continues improving. Newer home testing devices incorporate additional sensors, better algorithms, and validity checks that flag unreliable data. But they’re not replacing the comprehensive physiologic monitoring that in-lab polysomnography provides.

There’s probably a middle ground where home testing serves as an effective screening tool for straightforward cases while maintaining appropriate access to in-lab studies for complex presentations. Getting there requires better patient selection criteria, improved interpretation standards, and insurance policies that don’t create financial barriers to comprehensive testing when clinically indicated.

The risk is that cost considerations and convenience factors drive continued expansion of home testing beyond its appropriate clinical scope. That would be efficient in the short term and problematic in the longer term as undertreated sleep disorders contribute to cardiovascular disease, accidents, and reduced quality of life.

Sleep apnea testing doesn’t need to be one-size-fits-all. Matching the testing approach to patient complexity and clinical presentation would optimize both resource utilization and diagnostic outcomes. That requires clinicians to think more carefully about which test is appropriate for which patient, rather than defaulting to whatever’s easiest or cheapest.